Camnutra Ltd ^Company

CamNutra’s mission is to protect people against chronic health conditions using proprietary natural healthcare products which are clinically-proven by the world’s leading research institutions. CamNutra’s first product is Ateronon, which has been developed to protect against cardiovascular disease. It is the result of over £12m of development and has been the subject of clinical testing by teams from each of Cambridge and Harvard Universities. Research by Cambridge University published in June 2014 showed Ateronon to give a significant improvement in endothelial function in patients already taking statins. Ateronon is protected by a number of patents and is a naturally modified and highly bioavailable form of lycopene, which is a carotenoid derived from tomatoes. Ateronon is sold as an over the counter healthcare supplement both through www.ateronon.com as well as through the major retailers in the UK such as Holland & Barrett, Boots, J Sainsbury and Morrisons. The company has signed distribution deals in several overseas markets. CamNutra has a pipeline of further innovative, science-based natural healthcare products with intellectual property protection and clinically-proven benefit which it plans to bring to market. New products cover health indications such as cardiovascular disease, prostate health, diabetes and metabolic syndrome. CamNutra was formed in 2011 to acquire the IP and related assets of Ateronon and other innovative natural healthcare products. In 2012-13, the company received a total of £1.6m from the Cambridge Angels group of investors and having established a fast-growing sales base, is now in the process of raising further funds to accelerate its product roll-out and the development of its product pipeline.